Company news

Prescient Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Prescient Receives $1.03m R&D Tax Rebate

November 10, 2020

September 2020 Quarterly Update and Appendix 4C

October 19, 2020

Response to ASX Query

September 16, 2020

PTX Raises $7 million via Strongly Supported Placement

August 25, 2020

Appendix 4E and 2020 Annual Report

August 25, 2020

Successful SPP Closed Early

August 18, 2020

Extension of Share Purchase Plan

August 14, 2020

PTX Announces Cell Therapy Collaboration with Peter Mac

August 13, 2020

PTX-100 progresses to next cohort in basket clinical study

August 11, 2020

PTX-200 AML Trial Progresses to Next Dose Level

August 3, 2020

June 2020 Quarterly Update and Appendix 4C

July 21, 2020

2 PTX Assets Chosen in Doherty Institute COVID-19 Program

July 21, 2020

Trading Pause

July 20, 2020

Reinstatement to Official Quotation

May 25, 2020

PTX signs next-gen anti-cancer platform from Penn & Oxford

May 25, 2020

Voluntary Suspension

May 25, 2020

Pause in Trading

May 21, 2020

PTX-100 progresses to new dose, adds new site

April 21, 2020

March 2020 Quarterly Update and Appendix 4C

April 15, 2020

December 2019 Appendix 4C - Quarterly

January 31, 2020

PTX-200 High Overall Response in Ph2a Breast Cancer trial

December 22, 2019

Encouraging data from PTX-200 ovarian cancer trial

December 11, 2019

Third complete response in PTX-200 AML Trial

November 26, 2019

PTX in new CAR-T collaboration

November 17, 2019

1st patient dosed in trial for first in class drug PTX-100

November 13, 2019

Receipt of R&D Tax Rebate

November 7, 2019

Prescient Ausbiotech Ras Presentation

October 30, 2019

September 2019 Appendix 4C - Quarterly

October 29, 2019

Appendix 4E and 2019 Annual Report

August 25, 2019

June 2019 Appendix 4C - Quarterly

July 23, 2019

PTX Initiates Phase 1b Clinical Trial for PTX-100

July 10, 2019

Change to Exercise Price of Options

May 30, 2019

Canadian Patent Granted for PTX-200

May 15, 2019

Entitlement Offer Results and Shortfall Notification

April 26, 2019

March 2019 Appendix 4C - Quarterly

April 24, 2019

Despatch of Entitlement Offer Documents

April 3, 2019

Prospectus

March 24, 2019

Capital Raising Presentation - March 2019

March 24, 2019

Prescient Completes Equity Raising to Raise $9.1 Million

March 24, 2019

December 2018 Appendix 4C - Quarterly

January 31, 2019

Interim Durability Analysis of PTX-200 Breast Cancer Study

December 9, 2018

September 2018 Appendix 4C - Quarterly

October 31, 2018

Pipeline Collaboration for Next Generation Formulations

October 16, 2018

Change of Registry Address: Automic P/L - Sydney Office

September 28, 2018

Improved manufacturing route for PTX-100

September 2, 2018

Appendix 4E and 2018 Annual Report

August 31, 2018

PTX-200 AML Study Expanded

August 29, 2018

June 2018 Appendix 4C - Quarterly

July 31, 2018

US Patent Granted for PTX-200 for Ovarian Cancer Treatment

July 25, 2018

March 2018 Appendix 4C - Quarterly

April 23, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 44 decks. Every deck is listed under its year.